Skip to main
VANI

VANI Stock Forecast & Price Target

VANI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivani Medical Inc. is positioned favorably due to its innovative NPM-139 product, which demonstrates the potential to enhance the safety and tolerability of existing therapies like semaglutide, potentially leading to improved patient compliance and reduced therapy discontinuation rates. The compelling data indicating that NPM-139 can achieve and sustain approximately 20% weight loss over six months supports its advancement into clinical development, highlighting its promise in addressing chronic diseases. Additionally, the company's unique NanoPortal technology for long-term medication delivery adds a competitive edge, positioning Vivani Medical well within the biopharmaceutical industry as it explores expansion opportunities in both its Biopharm and Neuromodulation divisions.

Bears say

Vivani Medical faces significant risks that contribute to a negative outlook on its stock, primarily centered around the clinical and commercial viability of its key product, NPM-139. The company is confronted with the possibility of failing clinical trials, which would impede its ability to secure regulatory approval and ultimately affect the product’s commercial success due to market competition and penetration challenges. Furthermore, the potential for dilution presents an additional financial concern, as it may impact shareholder value and overall confidence in the company's future.

VANI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivani Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivani Medical Inc (VANI) Forecast

Analysts have given VANI a Strong Buy based on their latest research and market trends.

According to 1 analysts, VANI has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivani Medical Inc (VANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.